Australia's most trusted
source of pharma news
Posted 29 August 2025 AM
The Federal Government has held back from supporting recommendations from a Senate Inquiry for broad indication coverage for medicines that treat rare and less common cancers, as well as more timely and affordable access to novel medicines.
The Australian Government has responded to the findings of a Senate Inquiry into Equitable access to diagnosis and treatment for individuals with rare and less common cancers, including neuroendocrine cancer, and said it supported, or supported in principle, 31 of the 41 recommendations.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.